In this article, we will be taking a look at the 12 cheap healthcare stocks to buy heading into 2025.
The Resilience and Challenges of Global Healthcare Spending
Investing in healthcare equities is typically seen as protective during recessionary times. This is because, even in hard financial times, consumers usually do not reduce their usage of prescription drugs or other necessary healthcare services. National healthcare spending is expected to reach an estimated $4.8 trillion in 2023 and increase at a 5.6% annual pace between 2027 and 2032, according to the Centers for Medicare and Medicaid Services (CMS).
According to a World Health Organization report published in December 2023, worldwide healthcare spending reached a record high in 2021 at $9.8 trillion, or 10.3% of global GDP. Except in low-income countries, where government health spending declined as a result of their significant reliance on foreign aid, public health spending increased globally. While 11% of the world’s population lived in countries where yearly healthcare spending was less than $50 per person, high-income countries paid about $4,000 per capita in 2021. Additionally, low-income countries accounted for just 0.24% of global health spending, despite having 8% of the world’s population. The study claims that although public health spending rose dramatically during the peak of the COVID-19 epidemic, this increase is unlikely to last in the long term as countries now place a higher priority on economic problems such as high inflation, decreasing GDP, and mounting debt servicing. According to Dr. Bruce Aylward, WHO Assistant Director-General for Universal Health Coverage, Life Course:
“Sustained public financing on health is urgently needed to progress towards universal health coverage. It is especially critical at this time when the world is confronted by the climate crisis, conflicts, and other complex emergencies. People’s health and well-being need to be protected by resilient health systems that can also withstand these shocks.”
The impending collapse of the U.S. healthcare system, especially in terms of staff shortages and financial instability, is the most worrisome aspect of the healthcare sector. There is a serious manpower shortage in the healthcare sector. An additional 124,000 doctors are expected to be required by 2030, and by 2027, 800,000 registered nurses (RNs) are expected to retire. A startling 24% of staff registered nurses are currently leaving their jobs. In certain healthcare systems, this deficit has resulted in the shutdown of critical patient services like obstetrics, pediatrics, psychiatry, and intensive care units.
Nevertheless, the U.S. spends over twice as much on healthcare as the OECD average, despite these difficulties, and the average results are poorer. This discrepancy emphasizes how ineffective and unsustainable the current system is. Further taxing the revenue cycle and reducing the amount of money available for therapeutic treatments is the fact that 58% of hospital bad debt originates from insured patients. The future of the American healthcare system appears bleak when these elements are taken together. The industry faces a systemic collapse that could have serious repercussions for the economy and public health if substantial intervention and reform are not implemented.
A smiling healthcare professional, treating a patient with the PLEX platform.
Our Methodology
Our methodology involved selecting stocks with a market capitalization exceeding $10 billion and a price-to-earnings (P/E) ratio below 17. We then ranked these stocks based on their P/E ratios, as of December 22.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Here is our list of the 12 cheap healthcare stocks to buy heading into 2025.
12. Solventum Corporation (NYSE:SOLV)
P/E Ratio: 16.64
Standing twelfth among the cheap healthcare stocks to buy heading into 2025 is Solventum Corporation (NYSE:SOLV). It is a healthcare company that develops and manufactures solutions across four key segments: Medical Surgical (MedSurg), Dental Solutions, Health Information Systems, and Purification and Filtration. The MedSurg segment offers products like wound care, IV site management, sterilization tools, and surgical supplies. Its Dental Solutions include orthodontic products and restorative materials. The company’s Health Information Systems provides software for documentation, billing, coding, and data visualization to enhance clinical efficiency. In Purification and Filtration, Solventum Corporation (NYSE:SOLV) provides technologies to maintain hygiene and safety in healthcare settings.
To stabilize its operations, reposition for expansion, and optimize its portfolio, the company is putting a three-phase strategy into action. Phase 1 entails managing the company’s split from 3M while creating a new mission, hiring personnel, and restructuring for agility. The corporation is moving production lines from 67 factories to 29 Solventum plants as part of the separation, and two new facilities are being built.
Additionally, by cutting the number of distribution facilities from 122 to 73, Solventum Corporation (NYSE:SOLV) is reorganizing its supply chain and distribution. The management has modified commercial distribution patterns in more than 60 countries, and the rebranding initiatives are widespread, spanning more than 90 nations.
Solventum Corporation (NYSE:SOLV) reported $2.08 billion in revenue for the second quarter of 2024. Negative pressure wound therapy and antibacterial IV site management products were the main drivers of the MedSurg segment’s 1.8% annual growth. However, volume challenges from difficult market conditions caused a 2% loss in the Dental segment. The 360 Encompass and consistent performance management solutions drove the 3.6% growth in the HIS segment. Due to drinking water filtration performance, the Purification and Filtration segment had a minor decline of 0.9%.
11. United Therapeutics Corporation (NASDAQ:UTHR)
P/E Ratio: 16.41
United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on developing treatments for rare, life-threatening diseases, particularly cardiovascular disorders like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), as well as infectious diseases and pediatric oncology. The company produces pharmaceutical products such as prostacyclin analogs (Remodulin, Tyvaso, Orenitram) for PAH and PH-ILD, Adcirca (tadalafil) for PAH, and Unituxin (dinutuximab) for high-risk neuroblastoma in pediatric oncology.
United Therapeutics Corporation (UTHR) reported strong financial performance in Q3 2024, making it an attractive option for investors seeking affordable healthcare stocks. Revenue grew 23% year-over-year to $748.9 million, driven primarily by a 33% increase in Tyvaso sales, which reached $433.8 million. Other products, including Orenitram and Unituxin, also saw solid revenue growth, while Remodulin and Adcirca experienced slight declines. Net income rose 16% to $309.1 million, with diluted EPS increasing by 19% to $6.39. The growth was fueled by strong demand for pulmonary hypertension treatments, particularly Tyvaso, and the company expects key clinical and regulatory events in 2025 to further boost its growth prospects.
Analysts hold a consensus Moderate Buy rating on the stock. As of Q3 2024, 33 hedge funds held shares in the company as tracked by the Insider Monkey database. The largest shareholder in the company was VenBio Select Advisor with stakes worth $1.02 billion.
10. DaVita Inc. (NYSE:DVA)
P/E Ratio: 16.29
DaVita Inc. (NYSE:DVA) is a leading provider of kidney care services, specializing in dialysis treatments for chronic kidney disease and end-stage renal disease. The company operates dialysis centers across the U.S. and internationally, offering services like hemodialysis, peritoneal dialysis, pharmacy solutions, lab testing, and disease management. DaVita Inc. (NYSE:DVA)’s main customers are individuals needing dialysis, as well as healthcare providers, insurance companies, and government agencies seeking kidney care services.
DaVita Inc. (NYSE:DVA) has shown strong financial resilience in Q3 2024 despite challenges like supply chain disruptions and hurricanes. The company reported an adjusted operating income of $535 million, maintaining its full-year guidance of $1.91 billion to $2.01 billion. Adjusted EPS for Q3 was $2.59, with a full-year range of $9.25 to $10.05. Free cash flow reached $555 million, supporting its annual guidance of $950 million to $1.2 billion. Revenue per treatment (RPT) grew by 3.5% to 4%, despite flat treatment volumes.
DaVita Inc. (NYSE:DVA) managed operational challenges well, with minimal hurricane impact and ongoing efforts to control labor and medical costs. The corporation expects supply chain conditions to normalize by early 2025 and is preparing for a regulatory transition regarding oral-only drugs into Medicare Part B, which could enhance patient access and efficiency.
As of Q3 2024, 39 hedge funds held shares in the company as tracked by the Insider Monkey database. The largest shareholder in the stock was Berkshire Hathaway with stakes worth $5.9 billion.
9. Molina Healthcare, Inc. (NYSE:MOH)
P/E Ratio: 15.03
Molina Healthcare, Inc. (NYSE:MOH) is a managed care company providing health insurance and services, primarily to low-income individuals and families. It operates through government-sponsored programs like Medicaid, Medicare, and the Health Insurance Marketplace, offering insurance plans, primary care clinics, and comprehensive healthcare solutions.
Molina Healthcare, Inc. (NYSE:MOH) reported premium revenue of almost $9.7 billion in Q3 2024, which is a 17% increase from the previous year. A Medical Care Ratio (MCR) ratio of 89.2%, which shows that almost 90 cents of every dollar earned was spent on medical care, overshadowed this growth. This is much more than anticipated and above their long-term objective range of 85-88%. Higher medical expenditures in the Medicaid and Medicare segments were the primary cause of the higher MCR; California faced particular difficulties as a result of a retroactive premium rate cut that had a detrimental effect on margins.
The profitability of Molina Healthcare, Inc. (NYSE:MOH) was under strain despite the rise in sales. Although it was in line with forecasts, the adjusted profits per share (EPS) of $6.01 revealed a worrying trend in cost control. Although it was within their desired range, the adjusted pre-tax margin of 4.5% illustrates a situation in which costs are increasing more quickly than revenue growth in important categories.
According to the Insider Monkey database, 37 hedge funds held shares in the company in Q3 2024, with Durable Capital Partners being the largest shareholder, owning $361.4 million worth of stakes.
8. HCA Healthcare, Inc. (NYSE:HCA)
P/E Ratio: 13.88
HCA Healthcare, Inc. (NYSE:HCA) is a leading healthcare services provider operating a vast network of facilities and it stands eighth among the 12 cheap healthcare stocks to buy heading into 2025. It offers hospital care, surgical procedures, emergency services, diagnostics, mental health care, and specialized treatments like cardiology, oncology, neurosurgery, and orthopedics.
HCA Healthcare, Inc. (NYSE:HCA) delivered a strong financial performance in Q3 2024 despite hurricane impacts. Revenue rose 8% year-over-year to $17.487 billion, driven by a 4.5% increase in same-facility admissions. Net income was $1.27 billion, or $4.88 per diluted share, with adjusted EPS up 25% to $4.90 after accounting for hurricane impacts. Adjusted EBITDA reached $3.267 billion, with a 90-basis-point margin improvement. Operating cash flow totaled $3.515 billion. Despite disruptions from Hurricanes Helene and Milton, the company expects 3%-4% volume growth in 2025. Capital expenditures for 2024 are projected at $5 billion, supporting network expansion.
As of Q3 2024, 66 hedge funds owned shares in the company, according to the Insider Monkey database. The largest shareholder was First Eagle Investment Management, with stakes valued at $1.8 billion. Analysts have a consensus rating of Moderate Buy for the stock.
7. Elevance Health, Inc. (NYSE:ELV)
P/E Ratio: 13.62
Elevance Health, Inc. (NYSE:ELV), formerly Anthem, Inc., is a leading U.S. health insurance and benefits provider. It offers medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliates like Anthem Blue Cross, Wellpoint, and Carelon710. Focused on “whole health,” the company addresses physical, behavioral, and social needs to improve overall health and well-being.
Elevance Health, Inc. (NYSE: ELV) posted solid financial fundamentals despite difficulties in Q3 2024. Adjusted diluted profits per share were $8.37, and total operating revenue was $44.7 billion, up 5% year over year. However, the company’s Medicaid division had high medical costs, which resulted in a lowered full-year 2024 outlook of about $33 adjusted diluted EPS. With high single-digit percentage increases and at least 12% annual growth in adjusted diluted EPS, the company anticipates robust revenue growth in 2025. With plans to buy Kroger Specialty Pharmacy, expand its individual and family ACA plans in Florida, Maryland, and Texas, and enter three more states with individual exchange products, the firm is pursuing strategic expansion.
Elevance Health, Inc. (NYSE:ELV) introduced its 2025 Medicare Advantage Plans on October 1st, providing over 40.3 million eligible consumers in 23 states with customizable benefits and flexible options. 2.9 million Medicare beneficiaries are now served by the company’s linked health plans, and by 2025, the corporation hopes to offer individualized care that goes beyond medical treatment.
Artisan Partners’ Artisan Select Equity Fund stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its Q2 2024 investor letter:
“The top contributors to performance for the quarter were Alphabet, Lam Research, and Elevance Health, Inc. (NYSE:ELV). Elevance shares rose 5% during the quarter. The business has been performing well and has delivered good profit growth this year, despite a flat top line. It has largely navigated the challenges related to Medicaid redeterminations, which have caused temporary volatility in membership and healthcare utilization levels. Its vertical integration strategy is gaining traction, with strong revenue and profit growth at its Carelon Services business. Elevance’s shares are trading at 13X earnings, which is a very attractive investment proposition for a durable business that expects long-term earnings growth of over 12%.”
6. Biogen Inc. (NASDAQ:BIIB)
P/E Ratio: 13.60
Biogen Inc. (NASDAQ:BIIB) is a biopharmaceutical company focused on neurological and neurodegenerative diseases. Its key products include Avonex, Plegridy, Tysabri, and Tecfidera for multiple sclerosis; Spinraza for spinal muscular atrophy; Fumaderm for severe plaque psoriasis; and Fampyra for MS symptom management.
Due to problems with its Alzheimer’s medicine, Leqembi, and dwindling sales of important multiple sclerosis medications, Tecfidera and Tysabri, Biogen Inc. (NASDAQ:BIIB) has struggled in 2024, down more than 40% year-to-date and entering our list of cheap healthcare stocks among large-cap companies. Decreased royalties and contract manufacturing revenue are further challenges.
Analysts continue to see the company favorably despite this. Michael Yee, an analyst at Jefferies, kept his Buy recommendation on the firm with a $250 price target. The suggestion is based on encouraging results for Biogen Inc. (NASDAQ:BIIB)’s Alzheimer’s medication, Leqembi, in Europe. Based on genetic markers, the EMA has overturned its previous ruling and now suggests that Leqembi be approved for particular patient categories. Given that Europe might account for almost 30% of the drug’s worldwide sales, this choice is viewed as a huge opportunity.
Yee listed several difficulties, such as the need for the business to enhance its product pipeline, logistical barriers for patient adoption and diagnostic infrastructure, and delays in EU pricing and reimbursement procedures. Notwithstanding these problems, Leqembi’s approval among patient groups exhibiting a discernible improvement in cognitive function supports the market’s potential for expansion.
5. Universal Health Services, Inc. (NYSE:UHS)
P/E Ratio: 12.25
Universal Health Services, Inc. (NYSE:UHS) is a major healthcare provider operating in the U.S., Washington, D.C., Puerto Rico, and the U.K. It specializes in acute care, offering surgeries, internal medicine, oncology, emergency services, and behavioral health, including mental health and substance abuse treatments. UHS operates 27 acute care hospitals, 333 behavioral health inpatient facilities, 27 freestanding emergency departments, and 21 outpatient centers.
In Q3 2024, Universal Health Services, Inc. (NYSE:UHS) delivered strong financial results, reporting net income of $3.80 per diluted share and adjusted net income of $3.71. Revenue grew 8.6%, driven by a 1.5% rise in acute hospital admissions and a 10.5% increase in behavioral health revenues due to higher revenue per patient day. Expense management improved, with premium pay down 12% and physician costs stabilizing at 7.2% of revenues. Acute care hospital EBITDA rose 36% year-over-year, reflecting margin recovery. Upcoming hospital openings in Las Vegas, Washington D.C., and Florida are expected to drive future growth. Pending Medicaid supplemental programs may further boost revenues starting in 2024-2025.
As of Q3 2024, 50 out of 900 hedge funds held shares in the company, as tracked by Insider Monkey. The largest shareholder in the company was First Eagle Investment Management with stakes worth $1.06 billion. Analysts hold a consensus Moderate Buy rating on the stock.
4. CVS Health Corporation (NYSE:CVS)
P/E Ratio: 11.78
CVS Health Corporation (NYSE:CVS), standing fourth among the cheap healthcare stocks to buy heading into 2025, is a leading U.S. healthcare company with a multifaceted business model. It operates over 9,900 retail pharmacies offering medications, health products, and household items. The company provides pharmacy services, including prescription filling, specialty and mail-order services, and Pharmacy Benefit Management (PBM) through Caremark. CVS Health Corporation (NYSE:CVS) also offers health services via MinuteClinic for walk-in care and HealthHUB locations for chronic disease management and telehealth. Additionally, through its acquisition of Aetna, the corporation provides medical, dental, and vision insurance, enabling comprehensive healthcare solutions.
Customers’ access to services has been improved by CVS Health Corporation (NYSE:CVS) by utilizing its knowledge of health. Aetna, the company’s insurance division, unveiled SimplePay Health on October 16. The new service is an alternate health plan designed to accommodate self-insured consumers’ various needs. The strategy improves health outcomes while saving customers money.
On October 1, Aetna revealed its 2025 Medicare plans to meet its objectives. By guaranteeing that people have access to dependable and reasonably priced healthcare when needed, the plan aims to address the members’ most pressing health requirements. 59 million Medicare-eligible beneficiaries will have access to Aetna’s Medicare Advantage Prescription Drug (MAPD) plans when they extend to 44 states and Washington, DC, in 2025, for a total of 2,259 counties. In addition, Medicare Advantage (MA) by Aetna will offer a $0 monthly fee to 83% of Medicare-eligible enrollees in the United States.
In its Q2 2024 investor letter, Ariel Investments‘ Ariel Global Fund made the following statement about CVS Health Corporation (NYSE:CVS):
“American healthcare company, CVS Health Corporation (NYSE:CVS), also declined following disappointing earnings results and a subsequent reduction in full-year guidance. The miss was primarily due to increased utilization of Medicare Advantage plans and weakness in the health services segment driven by the loss of a large client and continued pharmacy client price improvements. In response, management reiterated its focus on improving margins and enhancing its positioning in Medicare Advantage. CVS believes the program can remain an attractive business for Aetna and CVS Health over time and will construct its bid for 2025 as a multi-year repricing opportunity across plan-level benefits. Meanwhile, CVS continues to return capital to shareholders through dividends and a recent accelerated share repurchase transaction.”
3. Novartis AG (NYSE:NVS)
P/E Ratio: 11.19
Novartis AG (NYSE:NVS), based in Basel, Switzerland, is a global healthcare company specializing in developing, manufacturing, and marketing prescription and generic drugs, as well as eye care products. Its focus spans oncology, cardiovascular, neurological, respiratory, immune, and infectious diseases. The company’s key products include Adakveo for sickle cell disease, Afinitor for cancer, Aimovig for migraines, and Beovu for macular degeneration, alongside generics and biosimilars through its Sandoz subsidiary.
Novartis AG (NYSE:NVS) announced a 10% increase in net revenues for the third quarter of 2024. Strong demand for important goods, such as Entresto and Cosentyx, which witnessed increases in sales of 26% and 28%, respectively, drove this growth. Additionally, the company’s core operating income increased by 20%, and its core margin increased to 40.1%, representing a 340 basis point improvement from the previous year. These factors highlight Novartis as one of the promising cheap healthcare stocks for investors to consider. In comparison to the prior year, core earnings per share (EPS) increased by 20% to $2.06.
Novartis AG (NYSE:NVS) reported a 20% increase in core operating income and an 11% increase in net sales for the first nine months of 2024. During this time, free cash flow hit a record $12.6 billion, up 15% from the previous year, and core EPS was $5.83, up 21%. The FDA just approved the company’s early breast cancer treatment, which could increase its target market by threefold.
Analysts hold a consensus Moderate Buy rating on the stock. As of Q3 2024, 24 hedge funds as tracked by the Insider Monkey database, held shares in the company. The largest shareholder was Renaissance Technologies with stakes worth $264.4 million.
2. Edwards Lifesciences Corporation (NYSE:EW)
P/E Ratio: 10.73
Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company specializing in devices for cardiovascular diseases, including structural heart disease and critical care. Its products include surgical and transcatheter heart valves (e.g., SAPIEN valves), hemodynamic and pressure monitoring devices, and vascular solutions like Fogarty catheters and carotid shunts.
In Q3 2024, Edwards Lifesciences Corporation (NYSE:EW) delivered strong financial performance, surpassing earnings expectations. Their revenue grew 9.6% on a constant currency basis to $1.35 billion which was driven by robust results in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). The company reported an adjusted EPS of $0.67, slightly exceeding the projected $0.665, reflecting its ability to sustain profitability while investing in growth.
The corporation’s TAVR segment saw a 6% increase in global sales, reaching $1 billion, with the U.S. market performing consistently and Europe benefiting from the launch of the SAPIEN 3 Ultra RESILIA valve. Meanwhile, TMTT sales surged 74% year-over-year to $91 million which was driven by strong adoption of the PASCAL repair system and the EVOQUE tricuspid replacement system. Full-year guidance for TMTT remains at the higher end of $320 million to $340 million. In the surgical segment, revenue rose 5% to $240 million which was supported by innovative technologies such as INSPIRIS, MITRIS, and KONECT.
The company’s strategic acquisitions, including JC Medical, JenaValve, and Endotronix, have expanded its presence in new therapeutic areas and bolstered its leadership in structural heart disease. Regulatory milestones, such as the CE mark approval for the Alterra system for congenital heart patients and U.S. approval of the 56mm EVOQUE valve, further enhance the company’s growth trajectory.
As of Q3 2024, 55 hedge funds held shares in the company as tracked by the Insider Monkey database. The largest shareholder was Fisher Asset Management with stakes worth $599 million.
1. Centene Corporation (NYSE:CNC)
P/E Ratio: 10.29
Centene Corporation (NYSE:CNC) is a multinational healthcare company specializing in health insurance and managed care services for government-sponsored programs like Medicaid, Medicare, and the Health Insurance Marketplace. It offers services such as managed care plans, pharmacy benefits management, telehealth, dental benefits, care management software, and home-based care. The company primarily serves state governments, individuals, families, employer groups, correctional facilities, and commercial organizations.
The Q3 results of Centene Corporation (NYSE:CNC) showed strong advancements in Medicaid stabilization, Medicare Star rating enhancement, and marketplace expansion. Additionally, the business is still on course to meet its annual objectives while setting itself up for long-term success. With an adjusted EPS of $1.62, the company’s Q3 2024 results are above forecasts thanks to advantageous tax timing. As redeterminations came to an end, the number of Medicaid members steadied at 13 million, with 30% of disenrolled people returning, despite short-term difficulties brought on by gaps. For investors looking at cheap healthcare stocks with solid growth potential, Centene Corporation (NYSE:CNC) offers a compelling choice. The second half of the year is expected to see rate increases of 4.5% to 5%, with the Medicaid Health Benefits Ratio (HBR) standing at 93.1%.
The percentage of participants in 2025 with a Medicare Star Rating of 3.5 or higher increased from 23% to 46%. In 2025, Medicare Advantage revenue is projected to be between $14 and $16 billion. With consistent margins anticipated, marketplace membership increased 22% year over year to 4.5 million. The corporation’s operational initiatives, such as AI for provider contracts, helped generate $36.9 billion in revenue in the third quarter. Lastly, Centene (NYSE:CNC) bought back $1.6 billion worth of shares despite the cash flow impacts of rate hikes.
Regarding Centene Corporation (NYSE:CNC), Oakmark Select Fund wrote the following in its investor letter for Q2 2024:
“Centene Corporation (NYSE:CNC) is one of the largest health insurers in the U.S. The company specializes in three major government-sponsored programs: Medicaid, Marketplace, and Medicare Advantage, each of which benefits from long-term secular tailwinds. In Medicaid, states are steadily outsourcing their programs to companies like Centene to reduce costs and improve care quality. Managed Medicaid penetration has increased throughout the past decade and we expect further gains over time. In Marketplace, growth is driven by the trend toward more individuals buying health insurance. Centene holds the #1 market share in both of these programs and is well-positioned to capitalize on their continued growth. Finally, we believe management is successfully turning around Centene’s Medicare business and expect the division to generate positive earnings over time. After adjusting for losses stemming from Centene’s Medicare business, we were able to purchase shares at a single-digit P/E multiple, which we think is too cheap for a leading, secularly growing Medicaid company and an improving Medicare business.”
Overall, CNC ranks first among the 12 cheap healthcare stocks to buy heading into 2025. While we acknowledge the potential of healthcare companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CNC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
